市場調查報告書
商品編碼
1466106
伴同性動物藥品市場:依產品類型、適應症、動物類型、通路 - 2024-2030 年全球預測Companion Animal Pharmaceuticals Market by Product (Analgesics, Anti-infectives, Anti-inflammatory), Indication (Behavioral Disorders, Dermatologic Diseases, Infectious Diseases), Animal Type, Distribution Channel - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
伴同性動物藥品市場規模預計2023年為147.3億美元,2024年達到161.5億美元,預計2030年將達到282.1億美元,複合年成長率為9.71%。
伴同性動物醫學涵蓋獸醫學的一個分支,涉及狗、貓和馬等寵物的藥物的發現、開發、生產和銷售。這些藥物旨在治療和預防多種疾病,從糖尿病等慢性疾病到急性感染疾病和傳染病,並促進伴同性動物的健康和福祉。隨著伴同性動物成為家庭不可或缺的一部分,對其醫療保健的需求不斷增加。由於容易在動物和人類之間傳播的疾病的流行,伴同性動物的衛生保健需要更加敏感。然而,新藥經過嚴格的核准程序既耗時又昂貴,並且阻礙了藥物的開發。尋找具有成本效益的學名藥藥物學名藥替代品有可能開拓新的細分市場。獸藥公司正在根據個別動物的基因制定客製化治療計劃,而生物辨識技術可以使他們的產品脫穎而出。此外,在開發新疫苗和針對各種疾病的生物治療方法方面也進行了大量投資。
主要市場統計 | |
---|---|
基準年[2023] | 147.3億美元 |
預測年份 [2024] | 161.5億美元 |
預測年份 [2030] | 282.1億美元 |
複合年成長率(%) | 9.71% |
產品多種止痛藥,用於治療伴同性動物的一般疼痛和慢性疼痛
藥用飼料添加劑是混入飼料中用於治療或預防疾病或改善動物健康的物質。這些添加劑包括維生素、胺基酸、抗生素和各種其他專門針對伴同性動物健康問題的藥物。當需要直接從動物飲食中添加藥物並確保定期攝取並遵守給藥方案時,就需要添加藥物飼料添加劑。疫苗在預防伴同性動物感染疾病方面發揮著至關重要的作用。疫苗透過刺激免疫反應來抵抗病原體,並且通常根據動物的年齡、生活方式和接觸特定疾病的地理環境來接種。
鎮痛藥是用於緩解伴同性動物疼痛的藥物,無需鎮靜或麻醉。它通常用於治療骨關節炎、術後疼痛管理和急性損傷等慢性疾病。感染疾病物包括多種用於治療伴侶動物感染疾病的藥物,包括抗生素、抗真菌藥物和伴同性。發炎劑廣泛用於減輕寵物的發炎和腫脹,對於皮膚炎和消化系統疾病以及術後護理等疾病至關重要。殺寄生蟲劑是用於控制伴同性動物體內寄生蟲的藥物,例如跳蚤、蜱蟲、蟎蟲和蛔蟲。對這些產品的需求通常在寄生蟲最活躍的溫暖月份達到頂峰。
適應症日益關注伴同性動物抗菌素抗藥性和感染疾病的先進藥物的開發
伴同性動物的行為障礙包括焦慮、憂鬱和強迫行為等更嚴重的症狀,如攻擊性和分離焦慮。寵物皮膚病很常見,可能是由過敏、感染疾病和寄生蟲引起的。皮膚感染疾病需要藥物來快速緩解症狀並治療根本原因,同時將全身影響降至最低。使用局部藥物、洗髮精和全身性治療,如口服抗組織胺、類固醇和免疫調節劑。由細菌、病毒、真菌或寄生蟲引起的伴同性動物感染疾病需要高效、頻譜的治療方法。骨關節炎和寵物關節損傷等整形外科疾病需要能夠控制疼痛和發炎並維持關節功能的治療,包括非類固醇消炎劑(NSAID) 和多硫酸Glico。伴同性動物的疼痛管理對於急性和慢性疾病都很重要。鎮痛藥的需要是立即緩解疼痛,最好沒有重大副作用。這包括輔助性治療,如鴉片類鎮痛藥、非類固醇消炎劑和Gabapentin。
動物類型:作為伴同性動物飼養的狗數量增加,治療費用增加
貓容易感染某些疾病,例如貓免疫力缺乏病毒(FIV)、貓白血病病毒(FeLV)、關節炎和牙科疾病,因此需要特定的藥物。由於狗品種的多樣性及其相關的健康需求,狗藥品市場廣闊。此類別包括多種產品,包括疫苗、心臟病預防藥物、跳蚤和蜱蟲治療藥物、發炎藥物和行為健康藥物。馬藥品市場專注於解決馬獨特的生理和身體特徵的產品。疫苗、生殖健康治療和肌肉骨骼藥物(包括發炎和止痛藥物)的需求強勁。狗通常在所有健康類別中具有最多樣化的藥物需求,並得到最廣泛的產品和製造商的支持。貓科藥物市場更為小眾,但隨著貓慢性疾病更微妙的跡像被認知到並且專門的治療方法被開發出來,貓科藥物市場也在不斷成長。馬藥市場,分銷量小,但需求量大,且許多治療方法都是客製化的,因此單價較高。
分銷管道:透過線上管道提高伴同性動物藥物的可用性和便利性
網路藥局為寵物飼主購買藥品提供了方便的平台。這些管道全天候 (24/7) 提供服務,並提供有競爭力的價格和宅配服務。網路藥局對於優先考慮便利性或無法立即前往實體店或獸醫診所的消費者尤其有吸引力。零售藥局是伴同性動物藥物的另一個重要分銷點。現場獲取專家建議並立即獲得您的產品。喜歡面對面互動或需要緊急藥物的顧客通常會選擇零售藥局。由於獸醫的個人化和專業服務,獸醫醫院仍然是寵物飼主醫療用品的可靠來源。診所透過現場配藥的方式,提供了問診後處方箋的便利性和即時,以及專業指導的保障。這些診所通常直接從製造商或專門從事獸藥的經銷商處採購產品。獸醫醫院提供全面的醫療服務,並儲備更廣泛的伴同性動物藥物,包括專業藥物和緊急藥物。這些設施是解決需要先進治療和即時現場獲取各種藥物的複雜健康問題的首選。大型獸醫連鎖醫院通常與製造商合作,以確保關鍵藥物的穩定供應。
區域洞察
在美洲,伴同性動物藥物的使用率較高,反映出寵物數量眾多以及飼主對先進獸醫護理的偏好。美洲展現出強大的生產能力,許多大型製藥公司都向該地區擴張。亞太地區伴同性動物保有量不斷增加,動物用藥品。然而,使用模式正在多樣化,與動物健康意識和支出仍在發展的新興國家相比,日本、澳洲和韓國等國家顯示出高成長。由於生產成本降低和品質標準提高,中國和印度等國家正在成為重要的製造地。研究和開發方面的投資也很大,特別是在亞洲製藥業蓬勃發展的國家。歐洲擁有成熟的伴同性動物藥物市場,其特點是嚴格的監管標準以及對安全性和有效性的重視。對慢性病管理藥物和預防藥物的需求很高。歐洲地區擁有完善的生產設施,專注於符合歐洲藥品管理局 (EMA) 法規的高品質標準。
FPNV定位矩陣
FPNV定位矩陣對於評估伴同性動物藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對伴同性動物藥品市場供應商的現狀進行富有洞察力和深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,以獲得市場競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.伴同性動物藥品市場規模及預測為何?
2.伴同性動物藥品市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些?
3.伴同性動物用藥市場的技術趨勢和法規結構是什麼?
4.伴同性動物藥品市場主要供應商的市場佔有率為何?
5. 進入伴同性動物藥品市場的合適型態和策略手段是什麼?
[181 Pages Report] The Companion Animal Pharmaceuticals Market size was estimated at USD 14.73 billion in 2023 and expected to reach USD 16.15 billion in 2024, at a CAGR 9.71% to reach USD 28.21 billion by 2030.
Companion animal pharmaceuticals encompasses the branch of veterinary medicine that is involved in the discovery, development, production, and marketing of drugs for pets, such as dogs, cats, and horses. These pharmaceuticals are designed to treat or prevent a wide range of conditions, from chronic diseases such as diabetes to acute infections or infestations, enhancing the health and well-being of companion animals. As companion animals become more integral to families, there is a rise in the demand for their healthcare. The prevalence of diseases transferable between animals and humans prompts more vigilant healthcare practices for companion animals. However, navigating through rigorous approval processes for new drugs can be time-consuming and costly, impeding the process of drug and pharmaceutical development. Research into cost-effective generic alternatives to branded medication can open up new market segments. Veterinary pharmaceutical companies are expanding into tailored treatment plans based on individual animal genetics, and biometrics can differentiate offerings. Moreover, there have been significant investments in the development of new vaccines and biologic treatments for various diseases.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 14.73 billion |
Estimated Year [2024] | USD 16.15 billion |
Forecast Year [2030] | USD 28.21 billion |
CAGR (%) | 9.71% |
Product: Diverse range of analgesics to treat general and chronic pain in companion animals
Medicated feed additives are substances mixed with animal feed to treat or prevent diseases and improve animal health. These additives include vitamins, amino acids, antibiotics, and various other drugs that specifically target health issues in companion animals. The need for medicated feed additives arises when there is a requirement for direct incorporation of medication through the animal's diet, ensuring regular intake and adherence to the medication schedule. Vaccines play a pivotal role in preventing infectious diseases in companion animals. They work by stimulating the immune response to fight off pathogens and are often administered based on an animal's age, lifestyle, and geographic exposure to specific diseases.
Analgesics are medications used to relieve pain in companion animals without causing sedation or anesthesia. They are commonly prescribed for chronic conditions, including osteoarthritis, post-surgical pain management, or acute injuries. Anti-infectives comprise a range of drugs, including antibiotics, antifungals, and antivirals, that are used to treat infections in companion animals. Anti-inflammatory drugs are widely used to reduce inflammation and swelling in pets, and they are crucial for conditions such as dermatitis and gastrointestinal diseases and for post-operative care. Parasiticides are agents used to eliminate parasites from companion animals such as fleas, ticks, mites, and worms. Demand for these products typically peaks during warmer months when parasites are most active.
Indication: Rising focus on developing advanced pharmaceuticals for antimicrobial resistance and infectious diseases in companion animals
Behavioral disorders in companion animals can range from conditions such as anxiety, depression, and compulsive behavior to more severe manifestations such as aggression or separation anxiety. Skin conditions in pets are common and can be due to allergies, infections, or parasites. Skin infections require pharmaceutical products that offer quick relief of symptoms and target underlying causes with minimal systemic effects. Topicals, shampoos, and systemic treatments, including oral antihistamines, steroids, and immune-modulating drugs, are used. Infectious diseases in companion animals caused by bacteria, viruses, fungi, or parasites require treatments that are highly effective and have a broad spectrum of activity, which includes antibiotics, antifungals, antivirals, and parasite-specific medications. Orthopedic ailments, including osteoarthritis and joint injuries in pets, necessitate treatments that can manage pain and inflammation and preserve joint function and mostly require treatments with non-steroidal anti-inflammatory drugs (NSAIDs) and newer therapies such as polysulfated glycosaminoglycans. Pain management in companion animals is critical for both acute and chronic conditions. The need for pain medications is to provide immediate relief, ideally without significant side effects. This includes opioid analgesics, NSAIDs, and adjunctive therapies, including gabapentin.
Animal Type: Increased adoption of dogs as companion animals and rising expenditure on their treatments
Cats are prone to certain conditions such as feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), arthritis, and dental diseases, necessitating tailored pharmaceutical solutions. The canine pharmaceutical market is extensive due to the variety of breeds and their associated health needs. This segment covers a broad spectrum of products, including vaccines, heartworm prevention, flea and tick treatments, anti-inflammatories, and behavioral health medications. The equine pharmaceutical market focuses on products that address the unique physiological and size considerations of horses. There is a significant demand for vaccines, reproductive health treatments, and musculoskeletal system medications, including anti-inflammatories and pain management drugs. Dogs generally have the most diversified need for pharmaceuticals across all health categories, supported by the largest range of products and manufacturers. The feline pharmaceutical market is more niche but is growing, with an increasing recognition of the subtler signs of chronic conditions in cats and the development of specialized treatments. The equine market, while smaller in volume, commands higher unit prices due to the larger dosages required and the bespoke nature of many treatments.
Distribution Channel: Enhanced accessibility and convenience of attaining companion animal pharmaceuticals through online channels
Online pharmacies provide a convenient platform for pet owners to purchase medications. These channels are favored for their 24/7 availability, competitive pricing, and home delivery services. Online pharmacies are particularly appealing to consumers who prioritize convenience and those who may not have immediate access to physical stores or veterinary services. Retail pharmacies are another vital point of sale for companion animal pharmaceuticals. They offer on-spot expert advice and immediate product availability. Customers who prefer in-person interaction or are seeking urgent medications often choose retail pharmacies. Veterinary clinics remain a trusted source of pharmaceuticals for pet owners, largely due to the personal and professional service provided by veterinarians. By dispensing medications on-site, clinics offer a level of convenience and immediacy for prescription fulfillment after consultation, as well as the assurance of professional guidance. These clinics typically source their products directly from manufacturers or through veterinary-focused distributors. Veterinary hospitals provide comprehensive medical care and stock a more extensive range of companion animal pharmaceuticals, including specialized and emergency medications. These establishments are preferred for complex health issues requiring advanced treatment and immediate onsite access to a variety of drugs. Large animal hospital chains often partner with manufacturers to ensure a steady supply of critical medications.
Regional Insights
In the Americas, there is a high usage rate of companion animal pharmaceuticals, reflecting the substantial pet population and pet owners' inclination towards advanced veterinary care. The Americas demonstrates robust production capabilities, with many major pharmaceutical companies operating within the region. The APAC region is witnessing a growing adoption of companion animals, which is fuelling the demand for animal health products. However, the usage pattern is diversified with higher growth in countries such as Japan, Australia, and South Korea, compared to emerging markets where awareness and expenditure on animal health are still developing. Countries such as China and India are emerging as significant manufacturing hubs due to lower production costs and improving quality standards. There is also a notable investment in R&D, particularly in countries with a strong pharmaceutical industry in Asia. In Europe, there is a well-established market for companion animal pharmaceuticals characterized by stringent regulatory standards and a focus on safety and efficacy. The usage is marked by a high demand for chronic disease management products alongside preventive medications. The European region has well-established production facilities with a focus on high-quality standards compliant with the European Medicines Agency (EMA) regulations.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Companion Animal Pharmaceuticals Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Companion Animal Pharmaceuticals Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Companion Animal Pharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Alivira Animal Health Limited, Ashish Life Science Pvt. Ltd., Boehringer Ingelheim International GmbH, Century Pharmaceuticals Ltd., Ceva Sante Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, Elanco Animal Health Incorporated, Endovac Animal Health, LLC, Hester Biosciences Limited, Hipra Laboratories, S.A., Indian Immunologicals Ltd., Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Meiji Group, Merck & Co. Inc., Neogen Corporation, Norbrook Laboratories Ltd., Orion Corporation, Phibro Animal Health Corporation, SkyEc Pharmaceuticals Private Limited, Stanex Drugs and Chemicals Pvt Ltd., Tianjin Ringpu Biotechnology Co., Ltd., Veko Care, Vetbiolix, Vetneeds Group, Virbac S.A., Zoetis Inc., and Zydus Animal Health.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Companion Animal Pharmaceuticals Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Companion Animal Pharmaceuticals Market?
3. What are the technology trends and regulatory frameworks in the Companion Animal Pharmaceuticals Market?
4. What is the market share of the leading vendors in the Companion Animal Pharmaceuticals Market?
5. Which modes and strategic moves are suitable for entering the Companion Animal Pharmaceuticals Market?